These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9917108)

  • 1. Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
    Haubrich R; Richman D
    JAMA; 1999 Jan; 281(2):130-1. PubMed ID: 9917108
    [No Abstract]   [Full Text] [Related]  

  • 2. Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
    Clay PG; Rathbun RC; Slater LN
    JAMA; 1999 Jan; 281(2):130; author reply 131. PubMed ID: 9917107
    [No Abstract]   [Full Text] [Related]  

  • 3. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
    Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM
    JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintaining a low viral load with Nevirapine?
    TreatmentUpdate; 1998 Dec; 10(10):3-4. PubMed ID: 11366017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viramune triple combo reduces viral load below limit of detection.
    AIDS Patient Care STDS; 1997 Dec; 11(6):456. PubMed ID: 11361870
    [No Abstract]   [Full Text] [Related]  

  • 6. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.
    Conway B; Wainberg MA; Hall D; Harris M; Reiss P; Cooper D; Vella S; Curry R; Robinson P; Lange JM; Montaner JS
    AIDS; 2001 Jul; 15(10):1269-74. PubMed ID: 11426071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Researchers report sustained suppression of HIV with nevirapine--didanosine--zidovudine.
    Am J Health Syst Pharm; 1998 Jun; 55(11):1106, 1108. PubMed ID: 9626369
    [No Abstract]   [Full Text] [Related]  

  • 8. Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
    Weinstein B
    JAMA; 1999 Jan; 281(2):131. PubMed ID: 9917109
    [No Abstract]   [Full Text] [Related]  

  • 9. Viral load--how low is best?
    TreatmentUpdate; 1998 Dec; 10(10):2-3. PubMed ID: 11366016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viramune triple therapy shows suppression of HIV after 1 year, 7 months.
    AIDS Patient Care STDS; 1997 Dec; 11(6):456-7. PubMed ID: 11361871
    [No Abstract]   [Full Text] [Related]  

  • 11. Triple therapy in previously untreated patients reduces viral load below limit of detection.
    AIDS Patient Care STDS; 1996 Oct; 10(5):308-9. PubMed ID: 11361526
    [No Abstract]   [Full Text] [Related]  

  • 12. Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team.
    Raboud JM; Rae S; Vella S; Harrigan PR; Bucciardini R; Fragola V; Ricciardulli D; Montaner JS
    J Acquir Immune Defic Syndr; 1999 Nov; 22(3):260-6. PubMed ID: 10770346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.
    Luzuriaga K; Bryson Y; Krogstad P; Robinson J; Stechenberg B; Lamson M; Cort S; Sullivan JL
    N Engl J Med; 1997 May; 336(19):1343-9. PubMed ID: 9134874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rebound of plasma HIV viral load following prolonged suppression with combination therapy.
    Montaner JS; Harris M; Mo T; Harrigan PR
    AIDS; 1998 Jul; 12(11):1398-9. PubMed ID: 9708426
    [No Abstract]   [Full Text] [Related]  

  • 15. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy.
    Raboud JM; Montaner JS; Conway B; Rae S; Reiss P; Vella S; Cooper D; Lange J; Harris M; Wainberg MA; Robinson P; Myers M; Hall D
    AIDS; 1998 Sep; 12(13):1619-24. PubMed ID: 9764780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine.
    Conway B
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S130-4. PubMed ID: 10860897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukocytopenia due to zidovudine- and nevirapine-containing regimens in elderly patients with HIV infection.
    Yamamoto Y; Yasuoka A; Yasuoka C; Genka I; Teruya K; Kikuchi Y; Tachikawa N; Oka S
    Jpn J Infect Dis; 2000 Dec; 53(6):244-5. PubMed ID: 11227023
    [No Abstract]   [Full Text] [Related]  

  • 18. Quality of life outcomes of combination zidovudine- didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients.
    Bucciardini R; Wu AW; Floridia M; Fragola V; Ricciardulli D; Tomino C; Weimer LE; Pirillo MF; Mirra M; Marzi M; Giannini G; Galluzzo CM; Andreotti M; Massella M; Vella S;
    AIDS; 2000 Nov; 14(16):2567-74. PubMed ID: 11101069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The continuing evolution of HIV therapy.
    Boyle BA
    AIDS Read; 2003 Dec; 13(12):576-8, 582. PubMed ID: 14959692
    [No Abstract]   [Full Text] [Related]  

  • 20. Modeling the use of triple combination therapy in five countries: nevirapine, Zidovudine, and Didanosine.
    Biddle AK; Simpson KN
    Value Health; 2000; 3(3):186-201. PubMed ID: 16464183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.